A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Olpasiran (AMG 890) (a GalNAc conjugated Small Interfering RNA [siRNA]) in Subjects with Elevated Lipoprotein(a)

Project: Research

Project Details

StatusActive
Effective start/end date26/05/2025/05/25

Keywords

  • clinical trial
  • phase 2 study
  • treatment safety
  • treatment efficacy
  • heart disease